NOVARTIS
π¨πSwitzerland
- Country
- π¨πSwitzerland
- Ownership
- Public, Private
- Established
- 1996-01-01
- Employees
- 76K
- Market Cap
- $242.6B
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics of AEB071
Phase 1
Completed
- Conditions
- Healthy
- First Posted Date
- 2006-12-12
- Last Posted Date
- 2010-10-19
- Lead Sponsor
- Novartis
- Target Recruit Count
- 16
- Registration Number
- NCT00409929
- Locations
- π¨π
Novartis Investigative Site, Bern, Switzerland
Study to Explore the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Oral AHT956 in Healthy Subjects
Phase 1
Completed
- Conditions
- Healthy
- First Posted Date
- 2006-12-12
- Last Posted Date
- 2007-06-22
- Lead Sponsor
- Novartis
- Target Recruit Count
- 42
- Registration Number
- NCT00410228
- Locations
- π¨π
Novartis Investigative Site, Bern, Switzerland
Effect of Food on the Pharmacokinetics of AQW051 in Japanese Healthy Male Subjects
Phase 1
Completed
- Conditions
- Healthy
- First Posted Date
- 2006-12-11
- Last Posted Date
- 2007-06-22
- Lead Sponsor
- Novartis
- Target Recruit Count
- 54
- Registration Number
- NCT00409500
- Locations
- π―π΅
Novartis Investigative Site, Tokyo, Japan
Effects of Methylphenidate on Cellular Abnormalities in Children With Attention Deficit Hyperactivity Disorder (ADHD)
Phase 2
Completed
- Conditions
- Attention Deficit Hyperactivity Disorder
- Interventions
- Drug: Extended Release Methylphenidate (Ritalin LA ) plus Behavior TherapyBehavioral: Behavior Therapy
- First Posted Date
- 2006-12-11
- Last Posted Date
- 2011-05-17
- Lead Sponsor
- Novartis
- Target Recruit Count
- 142
- Registration Number
- NCT00409708
- Locations
- πΊπΈ
Novartis Pharmaceuticals Investigational site, Houston, Texas, United States
Efficacy and Safety of Aliskiren and Valsartan Versus Placebo in Patients Stabilized Following an Acute Coronary Syndrome
Phase 2
Completed
- Conditions
- Post Acute Coronary SyndromeMyocardial Ischemia
- Interventions
- First Posted Date
- 2006-12-11
- Last Posted Date
- 2011-04-19
- Lead Sponsor
- Novartis
- Target Recruit Count
- 1101
- Registration Number
- NCT00409578
- Locations
- πΈπͺ
Investigative Site, Investigative Site, Sweden
Safety and Efficacy of Valsartan and Amlodipine Combined and Alone in Patients With Hypertension.
Phase 3
Completed
- Conditions
- Hypertension
- First Posted Date
- 2006-12-11
- Last Posted Date
- 2023-10-12
- Lead Sponsor
- Novartis
- Target Recruit Count
- 1930
- Registration Number
- NCT00409760
- Locations
- π©πͺ
Sites in Germany, Multiple Locations, Germany
Safety and Efficacy of Valsartan and Amlodipine Combined and Alone in Hypertensive Patients
Phase 3
Completed
- Conditions
- Hypertension
- First Posted Date
- 2006-12-11
- Last Posted Date
- 2011-11-08
- Lead Sponsor
- Novartis
- Target Recruit Count
- 1259
- Registration Number
- NCT00409643
- Locations
- π©πͺ
Sites in Germany, Germany, Germany
πΊπΈNovartis Pharmaceuticals, East Hanover, New Jersey, United States
One Year Study to Evaluate the Safety of the Combination of Valsartan and Amlodipine in Patients With Hypertension
Phase 3
Completed
- Conditions
- Hypertension
- First Posted Date
- 2006-12-11
- Last Posted Date
- 2011-11-08
- Lead Sponsor
- Novartis
- Target Recruit Count
- 1293
- Registration Number
- NCT00409851
- Locations
- πΊπΈ
Novartis Pharmaceuticals, East Hanover, New Jersey, United States
Acute Safety, Tolerability, Feasibility and Pharmacokinetics of Intrath. Administered ATI355 in Patients With Acute SCI
Phase 1
Completed
- Conditions
- Acute Spinal Cord Injury
- Interventions
- Drug: ATI355
- First Posted Date
- 2006-12-04
- Last Posted Date
- 2020-02-11
- Lead Sponsor
- Novartis
- Target Recruit Count
- 52
- Registration Number
- NCT00406016
- Locations
- π¨π
Novartis Investigative Site, Zuerich, Switzerland
π¨πNovartis Investigative site, Zurich, Switzerland
A Study of Three Doses of TCH346 in Patients With Early Parkinson's Disease to Evaluate Safety and Efficacy
Phase 1
Completed
- Conditions
- Parkinson's Disease
- First Posted Date
- 2006-12-04
- Last Posted Date
- 2011-11-23
- Lead Sponsor
- Novartis
- Target Recruit Count
- 301
- Registration Number
- NCT00407212
- Locations
- π«π·
Novartis Investigative Site, Paris, France
Β© Copyright 2025. All Rights Reserved by MedPath